[
  {
    "id": 1,
    "text": "What is your typical first-line therapy for newly diagnosed moderate COPD?"
  },
  {
    "id": 2,
    "text": "How do cost and access influence your choice of inhaler device and molecule?"
  },
  {
    "id": 3,
    "text": "When do you escalate from dual bronchodilation to adding inhaled corticosteroids?"
  },
  {
    "id": 4,
    "text": "How do you incorporate GOLD 2025 recommendations into practice?"
  },
  {
    "id": 5,
    "text": "Describe your approach to exacerbation prevention and follow-up scheduling."
  },
  {
    "id": 6,
    "text": "How do you tailor therapy for patients with frequent exacerbations and eosinophilia?"
  },
  {
    "id": 7,
    "text": "What non-pharmacologic interventions do you emphasize (rehab, vaccines, smoking cessation)?"
  },
  {
    "id": 8,
    "text": "How does rural vs urban care setting change your management of COPD?"
  },
  {
    "id": 9,
    "text": "How do payer policies and prior authorization affect your prescribing for COPD?"
  },
  {
    "id": 10,
    "text": "What\u2019s your view on initiating triple therapy earlier in the disease course?"
  },
  {
    "id": 11,
    "text": "How do you handle inhaler technique training and adherence monitoring?"
  },
  {
    "id": 12,
    "text": "When do you consider roflumilast or macrolides for exacerbation reduction?"
  },
  {
    "id": 13,
    "text": "How do comorbidities (CV disease, diabetes, OSA) change your COPD plan?"
  },
  {
    "id": 14,
    "text": "Describe your approach to pulmonary rehab referrals and barriers you face."
  },
  {
    "id": 15,
    "text": "How do you monitor and step-down therapy when patients are stable?"
  },
  {
    "id": 16,
    "text": "What\u2019s your perspective on biologics or novel mechanisms in COPD?"
  },
  {
    "id": 17,
    "text": "How do you coordinate with primary care and pharmacists for COPD management?"
  },
  {
    "id": 18,
    "text": "How does academic vs community practice shape your therapy choices?"
  },
  {
    "id": 19,
    "text": "How do you counsel patients about adverse effects and risk\u2013benefit tradeoffs?"
  },
  {
    "id": 20,
    "text": "Describe a typical follow-up cadence after therapy changes."
  },
  {
    "id": 21,
    "text": "Which patient factors push you toward nebulized therapies?"
  },
  {
    "id": 22,
    "text": "How do you evaluate and respond to frequent exacerbators with low eosinophils?"
  },
  {
    "id": 23,
    "text": "What role do spirometry and symptom scores play in your decisions?"
  },
  {
    "id": 24,
    "text": "How do you approach patients with poor inhaler technique despite training?"
  },
  {
    "id": 25,
    "text": "How do clinical guidelines influence your practice vs. experiential learning?"
  },
  {
    "id": 26,
    "text": "What\u2019s your stance on step-up vs. step-down in maintenance therapy?"
  },
  {
    "id": 27,
    "text": "How does patient socioeconomic status shape your treatment plans?"
  },
  {
    "id": 28,
    "text": "What metrics do you track to assess COPD control over time?"
  },
  {
    "id": 29,
    "text": "What innovations in COPD care are you most excited about?"
  },
  {
    "id": 30,
    "text": "How do you adjust care for limited access (transportation, specialty pharmacy)?"
  }
]